Beximco Pharmaceuticals reported a 6.3% rise in net revenue to BDT 14,657.9m for the first quarter ended 30 September, up from BDT 13,794.8m a year earlier.
The AIM-listed generic drugmaker and active pharmaceutical ingredient manufacturer posted profit after tax of BDT 2,596.9m, up 8.1% from BDT 2,401.3m in the comparable quarter, with earnings per share rising to BDT 5.72 from BDT 5.30.
Gross profit improved to BDT 7,175m from BDT 6,662.1m, though operating expenses also climbed, with selling, marketing and distribution costs up to BDT 3,392.2m from BDT 3,013.6m. Finance costs fell to BDT 105.9m from BDT 186.3m, helping lift profit before tax to BDT 3,425m from BDT 3,119.7m.
Cash and cash equivalents stood at BDT 8,466.3m at quarter-end, up from BDT 6,668m at the end of the prior financial year on 30 June. Net cash generated from operating activities rose to BDT 3,593.7m from BDT 2,737.8m a year earlier.
"We are pleased to share today's results which demonstrate the underlying strength and resilience of Beximco Pharma's business," said Managing Director S. M. Rabbur Reza, adding that the company continues to deliver growth "despite the ongoing macro-economic challenges."
Read more about Beximco Pharmaceuticals
- 26/06/26Beximco Pharma posts 11% revenue rise as export sales surge 38%
- 24/06/26Beximco Pharma half-year profit surges 36% as domestic and export sales both accelerate
- 22/06/26Beximco Pharma delivers first doses of generic cystic fibrosis treatment at 96% discount to US price
The quarter's growth follows a full year to 30 June 2025 in which net revenue rose 10.7% to BDT 49,120.4m and profit after tax increased 19.3% to BDT 6,998.9m, a period in which exports grew 37.7% to outpace domestic sales growth of 8.7%.
Net asset value per share stood at BDT 144.90 at 30 September, up from BDT 124.34 a year earlier.
